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BACKGROUND: Radiotherapy is central in the treatment of cervical cancer. The formation of DNA double-strand breaks is considered
to be critical for the radiotherapeutic effect. The non-homologous end joining (NHEJ) proteins DNA–PKcs, Ku70 and Ku86 have a
major role in repairing DNA lesions. The objective of this study was to analyse if the expression of DNA–PKcs, Ku70 and Ku86 and
their downstream signalling molecules p53, p21 and Mdm-2 are altered in residual cervical tumours after radiotherapy.
METHODS: Retrospective analysis of 127 patients with cervical cancer stage IB-IIA treated with preoperative radiotherapy and radical
surgery, revealed residual tumour in the cervical specimen in 30 patients. In 22 cases tumour material from residual and
corresponding primary tumour were retrieved and the expression of DNA–PKcs, Ku86, Ku70, p53, p21 and Mdm-2 were assessed
by immunohistochemistry.
RESULTS: Residual tumours showed increased frequency of DNA–PKcs (P¼0.037), Ku70 (P¼0.018), Ku86 (P¼0.008) positive cells.
A correlation in DNA–PKcs expression between primary and residual tumours was found. The frequency of p21-positive cells was
decreased (P¼0.007) in residual tumours whereas no change in p53 or Mdm-2-positive cells were observed.
CONCLUSION: Our results show that cervical carcinoma surviving radiotherapy have an increased DNA–PK expression. Studies on
larger patient cohorts are needed to allow an interpretation that an upregulation of DNA–PK function may be part of a
radioresistance mechanism within this tumour type.
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Radiotherapy (RT) is an established treatment modality for
cervical carcinoma. There are, however, cases not responding
properly to such treatment and an increased understanding of the
underlaying molecular processes leading to radioresistance may
lead to novel radiosensitising strategies.
Analysis of markers in cervical tumour specimens before RT
have shown that hypoxia (Fyles et al, 1998; Haensgen et al, 2001)
as well as increased survival signalling through Her-2 (Lee et al,
2005), epidermal growth factor receptor (EGFR) or insulin-like
growth factor receptor (IGFR) (Kim et al, 2006) are predictive for
lack of RT response.
The most critical DNA lesion induced by radiation is DNA
double-strand breaks (DNA dsbs) and in mammalian cells these
lesions are predominantly repaired by non-homologous end
joining (NHEJ) (Hefferin and Tomkinson, 2005). Central in the
NHEJ process is the binding of Ku70/Ku86 proteins to the free
DNA ends followed by recruitment of the catalytic subunit
of DNA-dependent protein kinase (DNA-PKcs), which in a
phosphorylation cascade regulate proteins operative in the DNA
dsbs ligation process (Hefferin and Tomkinson, 2005). The
importance of DNA-PK in radiation responses are illustrated by
studies on the human glioblastoma cell lines M059K and M059J,
proficient and deficient in DNA-PKcs, which show large differ-
ences in radioresponsiveness with the latter being hypersensitive
(Allalunis-Turner et al, 1995; Lees-Miller et al, 1995).
Apart from a critical role in DNA repair activated DNA-PKcs
also phosphorylate proteins involved in control of cell cycle
checkpoints and different cell-death pathways, the tumour
suppressor p53 being one example (Kastan et al, 1991; Lees-Miller
et al, 1992). Upon such phosphorylation p53 is stabilised and may
cause increased expression in the cell cycle regulator p21 or the
proapoptotic protein Bax (Bernstein et al, 2002).
The level of p53 is controlled by the human homologue to the
mouse double minute 2 protein (Mdm-2), which in a ubiquitin-
dependent manner targets p53 for degradation through the
proteasome (Haupt et al, 1997; Kubbutat et al, 1997). However,
in the majority of cervical cancers inactivation of p53 is mainly
caused by human papillomavirus infection (Scheffner et al, 1990).
Given the prominent role of DNA-PK in DNA-dsb repair, we and
others have examined if expression of DNA-PKcs or Ku proteins in
primary cervical tumour biopsies can predict an RT response
(Wilson et al, 2000; Beskow et al, 2006). Using immunohisto-
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schemical analysis of Ku70 and Ku80 on primary tumour biopsies
from stage I–III cervical cancer patients, Wilson et al (2000)
showed that all tumours with a low frequency of Ku70 or Ku80
immunopositive cells (o60%) were radiosensitive in a clonogenic
assay. We previously reported that the response to preoperative
intracavitary RT measured as pathologic complete remission in the
surgical specimen derived from patients with cervical cancer stage
IB and IIA could not be predicted by the expression of DNA-PK
proteins in primary tumour biopsies (Beskow et al, 2006).
Few clinical studies have so far addressed the question of how
radiotherapy may influence the expression of the DNA-PK complex
by analysing primary and residual tumour tissue after radiotherapy.
One may hypothesize that radioresistant tumours would display
increased function of a DNA-PK and p53-signalling network. In this
study, we aimed to compare the expression of DNA-PK proteins,
p53, p21 and Mdm-2 in primary tumours and corresponding
residual cervical tumours after RT using immunohistochemistry.
MATERIALS AND METHODS
Patients
This report on 22 patients is based on a retrospective analysis of
127 patients with cervical cancer FIGO stage IB-IIA consecutively
admitted to Karolinska University Hospital during January 1989–
December 1991 (Beskow et al, 2002). Treatment included
preoperative RT followed by radical surgery, which was performed
4 weeks after completed RT. In 22 out of 30 cases with residual
cervical tumours it was possible to retrieve tumour tissue from the
corresponding primary tumour. Clinical and pathological char-
acteristics of these 22 cases are shown in Table 1. The use of
patient materials was approved by the Ethical Committee (Ethical
permit; Dnr 00-343) at the Karolinska Institutet and informed
consent was obtained from all patients alive at the time of analysis.
Radiotherapy
Preoperative RT was given as brachytherapy to 18 patients,
whereas one patient received external beam radiation therapy and
three patients received a combination of external beam radiation
treatment and one or two fractions of brachytherapy. The treat-
ment given to each patient is described in Table 1. Brachytherapy
was applied according to ‘the modified Stockholm method’ using
two uterovaginal insertions with a 3-week interval (Beskow et al,
2002). During the period 1989–1991 our technique for brachy-
therapy gradually changed from a manual technique using radium
to a remote after-loading technique using cesium-137 in the
Selectron system. When introducing the after-loading technique,
the dose prescriptions were calculated to mimic the doses given
by the manual technique. Ten patients were treated with radium
applicators with a dosage quoted in milligram-hours of radium
(mghRa) calculated to a mean fraction dose of 3300mghRa and
a mean dose rate of 1.1Gyh
 1 to point A (ICRU, 1985). Eleven
patients received brachytherapy with the remote after-loading
technique using cesium-137 with a mean fraction dose of 22Gy
and a mean dose rate of 1.35Gyh
 1 to point A. Treatment with
external beam irradiation over the pelvis was given by linear
accelerators (6–21MV) to four patients with a daily fraction of
1.6Gy given 5 days per week. The prescribed doses varied between
13 and 30Gy (Table 1).
Immunohistochemistry
Expression of DNA-PKcs, Ku86, Ku70, Mdm-2, p53 and p21
proteins were assessed on formalin-fixed tumour biopsies taken
before RT and from the corresponding formalin-fixed surgical
specimens. Immunostainings were done using the avidin–biotin–
peroxidase complex- (ABC) technique according to the manufac-
turer’s instructions (Elite Standard Kit., Vector Laboratories,
Burlingame, CA, USA) and as previously described (Beskow
et al, 2006). Briefly, paraffin sections (4mm) were dewaxed and
rehydrated. The slides were boiled in citrate buffer (pH 6.0, 12min
at 800W and 20min at 250W), cooled and rinsed with phosphate-
buffered saline. After blocking with 1% BSA, the following primary
mouse monoclonal antibodies were used; DNA-PKcs, Ku86, Ku70
(Neo Markers, Fremont, CA, USA), p53 (clone DO-7, DAKO), p21
(clone EA10, Oncogene Research Products, Cambridge, MA, USA)
and Mdm-2 (SMP14, Santa Cruz Biotechnology, Santa Cruz, CA,
USA). The staining was visualised using a biotinylated secondary
Table 1 Characteristics of 22 patients with residual tumour after radiotherapy
Patient Age FIGO stage Tumour size (cm) Histopathological type Histopathological grade Preoperative radiotherapy
1 32 IB 3.0 Squamous Low Brachy Cs
a
2 43 IB 8.0 Squamous Moderate Brachy Ra
b
3 43 IB 5.0 Squamous Moderate Brachy Ra
4 41 IB 4.5 Adenocarcinoma High Brachy Cs
5 39 IB 6.0 Squamous Low Brachy Cs
6 28 IB 8.0 Squamous Low Brachy Ra
7 74 IB 5.0 Squamous High Brachy Ra
8 44 IB 5.0 Squamous High Brachy Cs
9 43 IB 1.0 Adenocarcinoma High Brachy Cs
10 33 IB 4.5 Adenosquamous Low Brachy Ra
11 39 IB 4.0 Adenocarcinoma Low Brachy Cs
12 39 IB 5.0 Adenocarcinoma Moderate Brachy Cs
13 28 IB 5.5 Adenocarcinoma Moderate Brachy Cs
14 38 IIA 6.0 Squamous Low Brachy Cs
15 54 IIA 3.5 Adenocarcinoma Moderate Brachy Ra
16 25 IIA 6.0 Squamous Low Brachy Ra
17 52 IIA 7.0 Squamous Low Ext 30Gy
c
18 79 IIA 5.0 Adenocarcinoma High 2 Ra+20Gy
d
19 71 IIA 4.0 Squamous Moderate Brachy Ra
20 45 IIA 4.0 Squamous Moderate Brachy Cs
21 25 IIA 5.0 Adenocarcinoma Low 30Gy+1Ra
e
22 43 IIA 6.0 Squamous Moderate 2Cs+13Gy
f
aBrachy Cs¼two fractions of brachytherapy using Cesium.
bBrachy Ra¼two fractions of brachytherapy using Radium.
cExternal beam radiation 30Gy.
dTwo fractions of
brachytherapy using Radium and external radiation 20Gy.
eExternal radiation 30Gy and one fraction of brachytherapy using Radium.
fTwo fractions of brachytherapy using
Caesium and external radiation total dose of 13Gy. Surgery was performed 3 months after end of radiotherapy.
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santibody followed by ABC and diaminobenzedine as a chromogene
(Vector Laboratories) and slides counterstained with haema-
toxylin. Evaluation of staining was carried out by a trained
pathologist in a blinded fashion and in each specimen 500 tumour
cells were counted. The percentage of stained cells was assessed
and the intensity graded as low, intermediate or strong.
Morphologically non-neoplastic cells in each specimen served as
internal negative controls for the staining procedure.
Statistical analysis
Comparison between primary biopsies and residual tumours were
determined using paired samples t-test and Wilcoxon’s Signed
Ranks test and the relations between primary and residual tumour
variables were evaluated with Spearman’s correlation test.
RESULTS
Higher frequency of DNA-PKcs, Ku70 and Ku86
immunopositive cells in residual cervical carcinoma
specimen
The percentages of cells staining positive for DNA-PKcs, Ku86 and
Ku70 in primary biopsies and residual tumours for each patient
are listed in Table 2. Residual tumours were found to display
higher percentages of DNA-PKcs immunopositive cells (Mean±
s.e.m.: 67.8±5.5), compared with the corresponding primary
tumour biopsy (Mean±s.e.m.: 57.8±5.2) (mean diff¼9.95,
s.d.¼20.4, P¼0.037). Similarly, the frequency of cells staining
positive for Ku70 and Ku86 were higher in residual than in
primary tumours. Expression of Ku70 in primary tumours ranged
from 48 to 95% (Mean±s.e.m.: 76.9±3.6) and from 51 to 98%
(Mean±s.e.m.: 86.8±3.2) in residual tumours after RT (mean
diff¼9.91, s.d.¼17.6, P¼0.018) (Figure 1A). The expression of
Ku86 varied between 0–98% (Mean±s.e.m. 66.7±5.4) in primary
tumours, whereas in residual tumours the percentage of positive
cells ranged from 55 to 100% (Mean±s.e.m.: 83.3±3.0) (mean
diff¼16.7, s.d.¼26.1, P¼0.008) (Figure 1B). Corresponding
analysis yielded P-values of 0.029, 0.006 and 0.004, respectively.
A correlation was observed between DNA-PKcs in primary
and residual tumours (rho¼0.55, P¼0.010) (data not shown).
In contrast, no correlations were found between primary and
residual tumours for neither Ku70 (rho¼0.126, P¼0.586) nor Ku
86 (rho¼0.323, P¼0.154) proteins. All three proteins displayed
a predominantly nuclear localisation. No overall differences in
staining intensity could be detected when comparing primary
and corresponding residual tumours for either DNA-PKcs or the
Ku proteins. As seen in Table 2, there is a variation in positivity
for the DNA-PK components among both the primary and residual
tumour tissue. However, these differences in immunopositivity
were not found to correlate with either clinical characteristics,
that is, tumour size, histopathologic type or grade or with the RT
regimen given.
Decreased frequency of p21 staining in residual cervical
carcinoma specimen
The frequency of tumour cells positive for p53, p21 or Mdm-2 in
tumour biopsies taken before therapy and in residual tumours is
presented in Table 3. The percentage of p21-positive cells was
decreased in residual tumours (Mean±s.e.m.: 9.35±3.4%) com-
pared with corresponding primary tumours (Mean±s.e.m.:
24.6±4.4%) (mean diff¼ 15.2, s.d.¼22.4, P¼0.007). Corres-
ponding analysis gave a P-value of 0.010 (Figure 1C). In contrast,
no significant difference in the frequency of p53-stained tumour
cells could be detected when primary tumour biopsies (Mean±
s.e.m.: 7.36±2.2%) and residual tumours were compared (Mean±
s.e.m.: 7.50±4.4%) (mean diff¼0.14, s.d.¼14.2, P¼0.965). The
Mdm-2 positivity of the cervical tumour cells ranged from 0
to 100%, with no overall difference in frequency between speci-
mens taken before (Mean±s.e.m.: 65.3±6.8%) and after RT
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15 33 33 0 51 73 22 36 55 19
16 71 94 23 94 95 1 90 98 8
17 19 27 8 62 65 3 59 71 12
18 10 30 20 78 50
19 73 83 10 65 98 33 80 84 4
20 81 91 10 91 55  36 86 85  1
21 28 31 3 79 97 18 52 92 40
22 51 54 3 76 93 17 49 77 28
Mean d 9.95 9.91 16.7
s.d. 20.4 17.6 26.1
d¼difference between post-treatment and pre-treatment values.
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s(Mean±s.e.m.: 65.6±9.4%) (mean diff¼0.32, s.d.¼39.8,
P¼0.970). Staining of p53 and p21 revealed a predominant
nuclear localisation, whereas Mdm-2 displayed a cytoplasmatic
staining pattern in 50% of the immunopositive primary tumours.
The majority of these cases also showed cytoplasmatic staining
in the corresponding residual tumours. No overall difference in
intensity of immunostaining was found when comparing primary
and residual tumours for p21, p53 or Mdm-2.
DISCUSSION
Impaired RT responsiveness of tumours is a major clinical
problem in several solid tumour types including cervical
carcinoma, in which RT is one of the key treatment modalities
used. Activation of DNA damage and DNA repair networks are
central in the molecular responses to radiation and within these
networks the DNA-PK complex have a major function. The results
of this study, comparing the expression of DNA-PK proteins in
primary tumour biopsies and corresponding residual cervical
carcinoma after RT, show a significant increase in frequency of
DNA-PKcs, Ku70 and Ku86-positive cells in the residual tumours.
To our knowledge this is the first study of clinical cervical
cancer in which DNA-PK complex expression has been examined
in both primary and residual tumour tissue after RT. There is one
study analysing DNA-PK proteins in oral squamous cell carcinoma
tumours pre- and post RT (Shintani et al, 2003). In that study,
patients were treated with external beam radiotherapy (EBRT) with
a total mean dose of 32.9Gy followed by surgery performed after
2–3 weeks. An increased expression of DNA-PKcs and Ku70 was
observed in residual tumour, whereas the percentage of the Ku80-
positive cells was similar in tumour tissue pre- and post RT. The
results reported by Shintani et al (2003) are partly in accordance
with ours, suggesting that upregulation of DNA-PKcs and Ku70
associates with radioresistance. However, the discrepancy with
respect to Ku80 between the studies is not clearly understood but
may be related to differences in treatment type, intracavitary vs
EBRT, or to the effect of chemotherapy, which was given to half of
Prior RT After RT
Figure 1 (A–C) Positive immunohistochemical staining of Ku70 (A) in poorly differentiated squamous cell carcinoma, Ku86 (B) in glassy cell
adenocarcinoma and p21 (C) in moderately differentiated adenocarcinoma of the cervix. Immunoreactivity is noted in nuclei of the tumour cells. After
radiotherapy an increased frequency of Ku70- and Ku86-positive tumour cells are seen parallel to a decrease in p21 positivity.
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sthe patients in the study of Shintani et al (2003) Moreover,
differences in tumour type as well as in the time span between end
of RT and surgery may contribute.
Several studies have been performed with the aim of identifying
molecular markers that could predict RT response in cervical
cancer (Fyles et al, 1998; Haensgen et al, 2001; Lee et al, 2005;
Kim et al, 2006). Thus it has been shown that the downstream
signalling component of EGFR, phosphorylated AKT, had a
significantly higher expression in radioresistant cases compared
with cancer tissue obtained from a radiosensitive group of cervical
cancer patients in whom radiosensitivity was defined as no
local recurrence at least 3 years after treatment (Kim et al, 2006).
In preclinical studies of tumour cell lines, radiation has been
shown to activate growth factor signalling networks, for example,
EGFR and IGFR leading to inhibition of radiation-induced cell
death (Dittmann et al, 2005a,b; Fuhrman et al, 2008). Interestingly,
recent data suggest that radiation-induced activation of EGFR
may result in accumulation of EGFR within the cell nucleus,
causing an increased function of the DNA-PK complex (Dittmann
et al, 2005b). Moreover, in a cervical carcinoma model it was
shown that addition of the PI3 kinase inhibitor, LY294002, sensi-
tised tumour cells to radiation in part by inhibiting the function of
DNA-PK (Fuhrman et al, 2008). In the context of these findings,
one may hypothesise that the increased DNA-PK observed in
residual cervical tumour tissue is a consequence of a radiation-
induced increase in growth factor receptor signalling. Ongoing
clinical studies in cervical cancer in which EGFR inhibition is
combined with RT will evaluate if such treatment combination will
increase radiosensitivity and if it involves inhibition of DNA-PK.
We also analysed the expression of p53, p21 and Mdm-2
proteins in cervical tumour tissue before and after RT.
A statistically significant decrease in the frequency of p21
immunopositive cells was found in residual tumours after RT
compared with corresponding primary tumour. In contrast, no
difference in the frequency of p53 and Mdm-2 positive cells was
observed between residual and primary tumours. Thus the
downregulation of p21 seems to be independent of p53. Such p53-
independent regulation has been previously described (Bernstein
et al, 2002). In tumour cell line models, it is well established that
a radiation-induced increase in p21 expression does occur
(Bernstein et al, 2002); however, few studies have examined how
radiation may influence p21 expression in a clinical setting. Yet,
Niibe et al (1999) reported that the number of p21- and p53-
positive cells increased after RT in tumour tissue taken before
treatment and 6h after the fifth dose of 1.8Gy from patients with
cervical cancer FIGO stage II-IVA. These results are in marked
contrast to ours, in which residual cervical tumours showed a
downregulation of p21 expression and may be explained by several
factors. Thus, in the study of Niibe et al (1999) the biopsies were
taken in the early phase of the radiation course, at a total dose of
approximately 10Gy, which is in contrast to the total dose of
at least 30Gy given in our study. Moreover, Niibe et al (1999)
analysed p21 expression at 6h post radiation, that is, at ongoing
radiation-induced cell cycle perturbations, while our analysis
was performed 4 weeks after end of RT. One potential mechanism
that could explain the observed decrease in p21 expression in RT
resistant tumours is that tumour cells with high p21 expression or
with capacity to induce p21 expression will be arrested either at G1
or at G2/M, whereas tumour cells with low p21 expression will
progress through the cell cycle after radiation and will thereby
constitute a larger proportion of the residual tumour.
In conclusion, we report here that residual cervical tumours
after RT show higher percentages of cells staining positive
for DNA-PKcs, Ku70 and Ku86 compared with corresponding
primary tumours. In contrast, we observe a decreased expression
of the cell cycle-regulating protein p21 in residual tumours. Our
results suggest that one mechanism of radioresistance in cervical
cancer may include upregulation of the DNA-PK proteins.
However, the findings reported in this study need to be confirmed
in larger patient materials in order to draw the conclusion of a
definite role of the DNA-PK proteins in radioresistance of cervical
carcinoma.
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